Guides/Reports
Regulatory Advisory: Detailed Summary of Recent CMS Interim Final Rule on COVID-19 Testing and Treatment
Rule also includes COVID-19 related changes to the Comprehensive Care for Joint Replacement Model
The Centers for Medicare & Medicaid Services (CMS) Oct. 28 announced an interim final rule establishing additional Medicare hospital payment to support Medicare beneficiaries’ access to COVID-19 vaccines and new treatments when they become available. CMS also released information on hospital billing for the outpatient administration of potential monoclonal antibody products; price transparency for COVID-19 tests; additional COVID-19 information relating to private health plans and Medicaid; and COVID-19-related changes to the Comprehensive Care for Joint Replacement (CJR) model. The rule also states that Medicare will cover any preventive vaccine at no cost to beneficiaries so long as it receives Food and Drug Administration approval via an emergency use authorization or Biologics License Application.
You must be logged in as a AHA Non-Fed Member to view the PDF file below with the full Regulatory Advisory.